dicycloverine Property

Boiling point:

142-143 °C(Press: 0.5 Torr)

Density 

0.990±0.06 g/cm3(Predicted)

pka

9.24±0.25(Predicted)

EPA Substance Registry System

[1,1'-Bicyclohexyl]-1-carboxylic acid, 2-(diethylamino)ethyl ester (77-19-0)

Safety

Hazardous Substances Data

77-19-0(Hazardous Substances Data)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

dicycloverine Chemical Properties,Usage,Production

Originator

Bentyl ,Merrell National ,US,1950

Uses

Anticholinergic.

Definition

ChEBI: The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularl that associated with irritable bowel syndrome.

Manufacturing Process

155 grams of 1-phenylcyclohexanecyanide, 350 cc of concentrated sulfuric acid and 1,130 cc of ethyl alcohol are refluxed vigorously for 48 hours. The remaining alcohol is then removed by vacuum distillation and the residue is poured into 1 liter of ice water. An oil separates which is extracted 3 times with 200 cc portions of petroleum ether, the extracts are combined and heated on a steam bath to remove the ether. The resulting crude ester may be used directly for the reesterification operation or it may be distilled to purify it first. A mixture of the ester so obtained, 155 grams of βdiethylaminoethanol and 800 cc of dry xylene are placed in a reaction vessel with about 2 grams of sodium. The vessel is heated in an oil bath at 150°- 160°C. A xylene-ethanol azeotrope distills over at about 78°-82°C over a period of 2 to 3 hours. The distillate is cooled and shaken with about 3 times its volume of water, the decrease in volume of the distillate being considered a measure of the amount of alcohol formed. When 80-90% of the theoretical amount of alcohol is obtained in the distillate the reaction mixture is subjected to vacuum distillation to remove most of the xylene and unreacted diethylaminoethanol. The residue is poured into 500 cc of benzene which is then extracted 3 times with 500 cc portions of water.
The washed benzene layer is diluted with an equal volume of ether and alcoholic hydrochloric acid is added until the mixture is acid to Congo red. A white crystalline solid forms which is dissolved in 300-400 cc of alcohol and diluted with ether to the point where precipitation starts. A few drops of butanone are added, the solution is cooled to -10°C, and filtered to recover the crystals which separate. The product is obtained in the form of white needles melting at 159°-160°C, in good yield.
13 parts of β-diethylaminoethyl 1-phenylcyclohexanecarboxylate hydrochloride, 125 parts of glacial acetic acid and 0.3 part of Adams' catalyst are heated to 70°C and shaken with hydrogen at 50 lb pressure until 90- 100% of the theoretical hydrogen is absorbed. The acetic acid is then removed by distillation and the residue recrystallized from butanone, giving the above product as a crystalline hydrochloride melting at 165°-166°C, in good yields. This product may also be prepared by reacting cyclohexyl bromide with cyclohexyl cyanide with the use of sodium amide followed by alcoholysis and reesterification.

brand name

Bentyl (Axcan Scandipharm);Abacid plus;Ametil;Babypasmil;Babyspasmil;Baycyclomine;Benacol;Colix;Cyclobex;Cyclocen;Diarrest;Diclophen;Eatongel;Esentil;Fomulex;Formulex;Gastrosilane;Icramin;Incramin;Incron;Inctacol-c;Isospamex;Kolanticon;Lagasediv;Menospasm;Merbantal;Neoquess;Nomocramp;Notensyl;Or-tyl;Pamin;Panakiron;Prinel;Protylol;Sawamin;Spactil;Spasmoban;Spastil;Tarestin;Viscerol.

Therapeutic Function

Spasmolytic

World Health Organization (WHO)

Dicycloverine, an anticholinergic agent with antispasmodic and local anaesthetic activity, was introduced in 1952 for treatment of functional conditions involving smooth muscle of the gastrointestinal tract. Its use in the treatment of colic in infants under six months of age has been associated with irritability and restlessness, convulsions and apnoea which has led the major manufacturer to issue revised global prescribing information in 1985 contraindicating the use of dicycloverine in this age group. Subsequently restrictive regulatory action directed to other available brands of this drug was taken in several countries. Preparations containing dicycloverine remain available in at least ten major markets.